21 May 2009
Generic products of immunosuppressive drugs according to incoming new emea guideline
P KunickiAnn Transplant 2009; 14(1): 75-76 :: ID: 880478
Abstract
Note for Guidance on the Investigation of Bioavailability and Bioequivalence,
CPMP/EWP/QWP/1401/98, EMEA, 26 July 2001, presents general rules for
generic drugs registration. For majority of generally acting drugs - simple
single-dose, 2-period, 2-sequence, crossover bioequivalence study in young
healthy volunteers in fasting state is usually performed. The decision regarding bioequivalence is based on 90% confidence intervals for AUC and Cmax ratios (test/reference) being within 80-125% for log-transformed data. For many years, such approach was criticized as inappropriate for some drugs with narrow therapeutic range, also called as "critical dose drugs". As a result of scientific debate, a new EMEA Guideline on the Investigation of Bioequivalence is coming into operation in 2009. The class of narrow therapeutic index drugs (NTDIs) is formally created for agents with steep concentration response relationship for efficacy and/or toxicity. These drugs require dosage individualisation based on therapeutic drug monitoring or titrated according to clinical response as a high risk of serious clinical consequences is expected in the event of too low or too high concentrations. All primary immunosuppressive drugs (cyclosporine, tacrolimus, sirolimus, and everolimus) can be easily and undoubtedly considered as NTDIs. However, the classification as NTDI must be made individually for particular drug. In these specific cases, the acceptance interval for AUC and Cmax ratios may need to be tightened to 90-111%. Moreover, in individual cases additional or alternative requirements might be set. Described standards oblige Registration Agencies to obey more restrictive rules for generic products of immunosuppressive drugs.
In Press
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860